PYPL−0.34moodIREN−0.46moodFRO+0.73moodCVX+0.44moodMRVL−0.26moodESTC+0.60moodBNTX−0.73moodAFRM+0.59moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodPYPL−0.34moodIREN−0.46moodFRO+0.73moodCVX+0.44moodMRVL−0.26moodESTC+0.60moodBNTX−0.73moodAFRM+0.59moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64mood

MRVL−0.26moodESTC+0.60moodBNTX−0.73moodAFRM+0.59moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodMRVL−0.26moodESTC+0.60moodBNTX−0.73moodAFRM+0.59moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10mood

RBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47mood

GLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31mood

GE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04mood

MELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88mood

ETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35mood

PD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodJNJ+0.58moodJOBY+0.08moodS−0.40moodAPP+0.08moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodJNJ+0.58moodJOBY+0.08moodS−0.40moodAPP+0.08mood

COST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodJNJ+0.58moodJOBY+0.08moodS−0.40moodAPP+0.08moodPYPL−0.34moodIREN−0.46moodFRO+0.73moodCVX+0.44moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodJNJ+0.58moodJOBY+0.08moodS−0.40moodAPP+0.08moodPYPL−0.34moodIREN−0.46moodFRO+0.73moodCVX+0.44mood

StockSays

TVRD

← Markets

TVRDTvardi Therapeutics, Inc.

Discussion

Nothing said here yet.

to join the conversation.

—

Wed, Aug 26
7:00 AMglobenewswire.comTvardi Therapeutics to Participate in Upcoming Investor Events
Fri, Aug 14
6:00 AMYahooTvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
Wed, Aug 12
7:00 AMYahooTvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
Thu, Jul 30
6:30 AMYahooTvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
Thu, Jul 9
9:52 AMYahooTVRD Stock Rallies 149% So Far This Week: Here's What You Should Know
Tue, Jul 7
6:00 AMYahooTvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
Fri, May 8
6:00 AMYahooTvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update

TVRD · Tvardi Therapeutics, Inc. — sentiment, insiders, filings